7,8-Benzoflavone | CAS:604-59-1 | Manufacturer ChemFaces

Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.

Viruses.2024, 16(7):1128.

Microchemical Journal2022, 182: 107874.

BMC Complement Altern Med.2017, 17(1):393

Journal of Phytopathology2021, 169,Issue11-12.

Fitoterapia.2022, 157:105130.

British Jou. Med.&Med. Research2014, 1802-1811

J Chromatogr A.2022, 1685:463640.

Current Traditional Medicine, 2021, 7:326-335(10).

Journal of Analytical Chemistry2017, 854-861

Current Analytical Chemistry2024, 20(8):599-610.

J Pharm Sci. 2008 Oct;97(10):4546-56.

Pharmacokinetics and bioavailability of the flavonoid 7,8-benzoflavone in rats.[Pubmed: 18257033 ]

The flavonoid 7,8-Benzoflavone was recently identified as one of the most potent inhibitors of breast cancer resistance protein (BCRP); however, little is known of the in vivo disposition of 7,8-Benzoflavone. The objective of this study was to investigate the pharmacokinetics and bioavailability of 7,8-Benzoflavone in rats.
METHODS AND RESULTS:
Three intravenous (5, 10, and 25 mg/kg) and three oral (12.5, 25, and 50 mg/kg) doses were administered to female Sprague-Dawley rats. Plasma samples were analyzed by high-performance liquid chromatography. Pharmacokinetic analysis was conducted by WinNonlin and ADAPT II. The dose-normalized plasma concentration versus time curves did not superimpose with each other, indicating the nonlinear pharmacokinetics of 7,8-Benzoflavone. 7,8-Benzoflavone exhibited a large volume of distribution (V(ss) approximately 1.5 L/kg) and rapid oral absorption (t(max) < 30 min). The bioavailability of 7,8-Benzoflavone was low (0.61-13.2%) and dose-dependent. A pharmacokinetic model with dose-dependent bioavailability, linear absorption and nonlinear elimination best described the pharmacokinetic profiles of 7,8-Benzoflavone.
CONCLUSIONS:
Using a 50 mg/kg oral dose of 7,8-Benzoflavone, we could significantly increase the AUC for the BCRP substrate nitrofurantoin, demonstrating the potential for BCRP-mediated drug interactions.

Product Name	7,8-Benzoflavone
CAS No.:	604-59-1
Catalog No.:	CFN94465
Molecular Formula:	C₁₉H₁₂O₂
Molecular Weight:	272.30 g/mol
Purity:	>=98%
Type of Compound:	Flavonoids
Physical Desc.:	Powder
Source:	The root exudates of Acroptilon repens.
Solvent:	Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price:	$40/20mg